Saltar al contenido

Vertex Pharmaceuticals Inc / MA (VRTX) stock: revenue, earnings & dividend

Vertex Pharmaceuticals Inc / MA (VRTX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener VRTX · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
12 bn $
Revenue growth
8.9 %
Revenue growth 5y (p.a.)
14.1 %
Net income
3.95 bn $
Net margin
32.9 %
Operating margin
34.8 %
Earnings per share (diluted)
15.32 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
25.6 bn $
Equity
18.7 bn $
Equity ratio
72.8 %
Return on equity
21.2 %
Cash
5.08 bn $
Operating cash flow
3.63 bn $
Free cash flow
3.19 bn $
Shares outstanding
253,537,674

History

Revenue by fiscal year

2016 1.7 bn $
2017 2.49 bn $
2018 3.05 bn $
2019 4.16 bn $
2020 6.21 bn $
2021 7.57 bn $
2022 8.93 bn $
2023 9.87 bn $
2024 11 bn $
2025 12 bn $

Net income by fiscal year

2016 -112.05 m $
2017 263 m $
2018 2.1 bn $
2019 1.18 bn $
2020 2.71 bn $
2021 2.34 bn $
2022 3.32 bn $
2023 3.62 bn $
2024 -535.6 m $
2025 3.95 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
202512 bn $3.95 bn $15.32 $–3.63 bn $
202411 bn $-535.6 m $-2.08 $–-492.6 m $
20239.87 bn $3.62 bn $13.89 $–3.54 bn $
20228.93 bn $3.32 bn $12.82 $–4.13 bn $
20217.57 bn $2.34 bn $9.01 $–2.64 bn $
20206.21 bn $2.71 bn $10.29 $–3.25 bn $
20194.16 bn $1.18 bn $4.51 $–1.57 bn $
20183.05 bn $2.1 bn $8.09 $–1.27 bn $
20172.49 bn $263 m $1.04 $–845 m $
20161.7 bn $-112.05 m $-0.46 $–236 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)